Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clarithromycin→

Clarithromycin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
81103-11-9
Molecular formula
C38H69NO13
Molecular weight
748 g/mol
Drug class
Macrolide Antimicrobial
Mechanism of action
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Indications / reported uses
  • Bronchitis
  • Chlamydia Infections
  • Duodenal Ulcer
  • Haemophilus Infections
  • Mycobacterium Infections, Nontuberculous
View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Clarithromycin Environmental Risk Assessment (ERA) (the Clarithromycin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.